medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 6

<< Back Next >>

Med Int Mex 2022; 38 (6)

Degree of response and survival analysis with the administration of steroid according to the Lille model in Mexican patients with alcoholic hepatitis

Ortiz-Montaño Y, Fuentes-Venegas A, Mendoza-García JG, Torres-Viloria A

Language: Spanish
References: 27
Page: 1162-1169
PDF size: 189.80 Kb.


ABSTRACT

Objective: To determine the degree of response to steroid treatment in patients with alcoholic hepatitis using the Lille model.
Materials and Methods: Descriptive, observational, retrospective and crosssectional study including files of patients with alcoholic hepatitis hospitalized in the Internal Medicine service of the General Hospital Dr. Manuel Gea González, Mexico City, from January 1st 2007 to December 31st 2011. The Lille model was applied in those patients who had received a steroid for at least 7 days to classify them according to the response (partial, complete or null).
Results: Forty-one files met the inclusion criteria, which were divided into 3 categories according to the Lille model: complete (‹ 0.18), partial (0.18-0.56) and null (› 0.56) responders. When evaluating the Lille model at 6 months of survival, a new cut of 0.9395 was obtained in relation to survival at one and six months. The Kaplan-Meier curves showed that there was a survival of 71.4% versus 25% (p = 0.003) in patients with a cut above and below 0.9395, respectively.
Conclusions: The cut-off point proposed by the Lille model does not correlate with the degree of response that patients with alcoholic hepatitis have in the Mexican population, so a new cut-off point of 0.9395 is proposed.


REFERENCES

  1. Lucey M, Mathurin P, Morgan TR. Alcoholic hepatitis.N Engl J Med 2009; 360: 2758-2769. doi: 10.1056/NEJMra0805786.

  2. Liangpunsakul S. Clinical characteristics and mortality ofhospitalized alcoholic hepatitis patients in the United States.J Clin Gastroenterol 2011; 45 (8): 714-9. doi: 10.1097/MCG.0b013e3181fdef1d.

  3. Sandahl TD, Jepsen P, Thomsen KL, Vilstrup H. Incidenceand mortality of alcoholic hepatitis in Denmark 1999–2008:a nationwide population based cohort study. J Hepatol2011; 54: 760-764. doi: 10.1016/j.jhep.2010.07.016.

  4. O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liverdisease.Hepatology 2010; 51: 307-328. doi: 10.1002/hep.23258.

  5. Dominguez M, Rincon D, Abraldes JG, Miquel R, ColmeneroJ, Bellot P, et al. A new scoring system for prognosticstratification of patients with alcoholic hepatitis. Am JGastroenterol 2008; 103: 2747-2756. doi: 10.1111/j.1572-0241.2008.02104.x.

  6. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E,Fartoux L, et al. The Lille model: a new tool for therapeuticstrategy in patients with severe alcoholic hepatitis treatedwith steroids. Hepatology 2007; 45: 1348-1354. doi:10.1002/hep.21607.

  7. Kosten TR, O’Connor PG. Management of drug and alcoholwithdrawal. N Engl J Med 2003; 348: 1786-1795. DOI:10.1056/NEJMra020617.

  8. Louvet A, Wartel F, Castel H, Dharancy S, Hollebecque A,Canva-Delcambre V, et al. Prospective screening of infectionin patients with severe alcoholic hepatitis treatedwith steroids: early response to therapy is the key factor.Gastroenterology 2009; 137: 541-548. doi: 10.1053/j.gastro.2009.04.062.

  9. Mathurin P, O’Grady J, Carithers RL, Phillips M, Louvet A,Mendenhall CL, et al. Corticosteroids improve short-termsurvival in patients with severe alcoholic hepatitis: metaanalysisof individual patient data. Gut 2011; 60: 255-260.doi: 10.1136/gut.2010.224097.

  10. Carithers RL Jr, Herlong HF, Diehl AM, Shaw EW, CombesB, Fallon HJ, et al. Methylprednisolone therapy inpatients with severe alcoholic hepatitis: a randomizedmulticenter trial. Ann Intern Med 1989; 110: 685-690. doi:10.7326/0003-4819-110-9-685.

  11. Mathurin P, Mendenhall C, Carithers RL Jr, Ramond MJ,Maddrey WC, Garstide P, et al. Corticosteroids improveshort term survival in patients with severe alcoholic hepatitis(AH): individual data analysis of the last three randomizedplacebo controlled double blind trials. J Hepatol2002; 36: 480-487. doi: 10.1016/s0168-8278(01)00289-6.

  12. Phillips M, Curtis H, Portmann B, Donaldson N, BomfordA, O’Grady J. Antioxidants versus corticosteroids in thetreatment of severe alcoholic hepatitis-a randomisedclinical trial. J Hepatol 2006; 44: 784-790. doi: 10.1016/j.jhep.2005.11.039.

  13. Imperiale TF, McCulloughs AJ. Do corticosteroids reducemortality from alcoholic hepatitis? Ann Intern Med 1990;113: 299-307. doi: 10.1053/j.gastro.2018.05.011.

  14. Rambaldi A, Saconato H, Christensen E, Thordlund K,Wetterslev J, Gluud C. Systematic review: glucocorticosteroidsfor alcoholic hepatitis – a Cochrane Hepato-BiliaryGroup systematic review with meta-analyses and trialsequential analyses of randomized clinical trials. AlimentPharmacol Ther 2008; 27: 1167-1178. doi: 10.1111/j.1365-2036.2008.03685.x.

  15. Cabre E, Rodriguez-Iglesias P, Caballeria J, Quer JC, Sanchez-Lombrana JL, Pares A, et al. Short- and long-term outcomeof severe alcohol-induced hepatitis treated with steroidsor enteral nutrition: a multicenter randomized trial. Hepatology2000; 32: 36-42. doi: 10.1053/jhep.2000.8627.

  16. Ramond MJ, Poynard T, Rueff B, Mathurin P, TheodoreC, Chaput JC, et al. A randomized trial of prednisolone inpatients with severe alcoholic hepatitis. N Engl J Med 1992;326: 507-512. DOI: 10.1056/NEJM199202203260802.

  17. Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, The´venotT, et al. Early switch to pentoxifylline in patients with severealcoholic hepatitis is inefficient in non-responders tocorticosteroids J Hepatol 2008; 48: 465-470. doi: 10.1016/j.jhep.2007.10.010.

  18. Mathurin P, Abdelnour M, Ramond MJ, Carbonnell N, FartouxL, Serfaty L, et al. Early change in bilirubin levels (ECBL)is an important prognostic factor in severe biopsy-provenalcoholic hepatitis (AH) treated by prednisolone. Hepatology2003; 38: 1363-1369. doi: 10.1016/j.hep.2003.09.038.

  19. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O.Pentoxifylline improves short-term survival in severe acutealcoholic hepatitis: a double-blind, placebo-controlled trial.Gastroenterology 2000; 119: 1637-1648. doi: 10.1053/gast.2000.20189.

  20. Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, BarraudH, et al. Pentoxifylline does not decrease short-termmortality but does reduce complications in patients withadvanced cirrhosis. Gastroenterology 2010; 138: 1755-1762. doi: 10.1053/j.gastro.2010.01.040.

  21. Tyagi P, Sharma P, Sharma BC, Puri AS, Kumar A, Sarin SK.Prevention of hepatorenal syndrome in patients with cirrhosisand ascites: a pilot randomized control trial betweenpentoxifylline and placebo. Eur J Gastroenterol Hepatol2011; 23: 210-217. doi: 10.1097/MEG.0b013e3283435d76.

  22. Krishna De B, Gangopadhyay S, Dutta D, Baksi SD, Pani A,Ghosh P. Pentoxifylline versus prednisolone for severe alcoholichepatitis: a randomized controlled trial. World J Gastroenterol2009; 15: 1613-1619. doi: 10.3748/wjg.15.1613.

  23. Spahr L, Rubbia-Brandt L, Pugin J, Giostra E, Frossard JL,Borisch B, et al. Rapid changes in alcoholic hepatitis histologyunder steroids: correlation with soluble intercellularadhesion molecule-1 in hepatic venous blood. J Hepatol2001; 35: 582-589. doi: 10.1016/s0168-8278(01)00190-8.

  24. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, JouetP, Piquet MA, et al. A double blind randomized controlledtrial of infliximab associated with prednisolone in acutealcoholic hepatitis. Hepatology 2004; 39: 1390-1397. doi:10.1002/hep.20206.

  25. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, AqelB, et al. A randomized, double-blinded, placebo-controlledmulticenter trial of etanercept in the treatment of alcoholichepatitis. Gastroenterology 2008; 135: 1953-1960. doi:10.1053/j.gastro.2008.08.057.

  26. Mathurin P, Moreno C, Samuel D, Dumortier J, SalleronJ, Durand F, et al. Early liver transplantation for severealcoholic hepatitis. N Engl J Med 2011; 365: 1790-1800.DOI: 10.1056/NEJMoa1105703.

  27. Garrido-García JR, Sánchez-Hernández G, Melchor-LopézA, Elizalde-Barrera CI, Sánchez-Vargas L. Pentoxifilinaversus esteroide en la sobrevivencia a corto plazo enhepatitis aguda alcohólica severa. Med Int Mex 2012;28 (3): 227-233.




2020     |     www.medigraphic.com